Studies have shown that decreased levels of sRAGE in patients with autoimmune disorders, such as MS (42), systemic lupus erythematosus (43), and Guillain-Barré syndrome (44), correlate with increased inflammatory activity and clinical manifestations, suggesting that reduced sRAGE may lead to enhanced RAGE activation and contribute to disease progression (41). Here, AGER is linked to Guillain-Barre syndrome.